Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients
Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients
This is a single center, multispecialty, randomized double blind placebo control feasibility
 clinical trial. The purpose is to evaluate the safety, feasibility and efficacy of
 percutaneous transluminal angioplasty in treating extracranial venous obstructive lesions,
 and its influence on the clinical outcomes of Multiple Sclerosis (MS) patients that have been
 found to have chronic cerebrospinal venous insufficiency (CCSVI).
Inclusion Criteria:

 -  Must be 18 years old or greater and less than or equal to 65 years of age

 -  Score of 0 to 7 on the EDSS scale

 -  Diagnosis of relapsing remitting or secondary progressive Multiple Sclerosis by a
 neurologist and confirmed by one of the independent study neurologists

 -  Presence of greater than or equal to 50 percent stenosis of the extracranial veins as
 determined by venogram

 -  Informed consent signed by patient

 Exclusion Criteria:

 -  Patient is unwilling to comply with the follow up

 -  Patient is pregnant

 -  Diagnosis of primary progressive MS by a certified neurologist confirmed by one of the
 study neurologists

 -  Presence of less than 50 percent stenosis of the extracranial veins as determined by
 venogram

 -  Presence of other medical illnesses or a psychiatric condition that in the opinion of
 the investigator may cause the subject to be non-compliant with the protocol
 requirements

 -  Life expectancy is less than one year

 -  Lack of mental capacity to consent

 -  Creatinine level of greater than 2.5 or is dialysis dependant

 -  Enrollment in another clinical study